Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma 1Leukemia 1Genetic Diseases, Inborn 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Transplantation × Clear all
NCT00212407 2018-11-02

New York Blood Center National Cord Blood Program

New York Blood Center

Phase EARLY_PHASE1 Terminated
4,476 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡